Literature DB >> 6871637

Prognostic factors in locally recurrent rectal carcinoma treated by radiotherapy.

R D James, R J Johnson, B Eddleston, G L Zheng, J M Jones.   

Abstract

An analysis has been made of the symptomatic response and survival of 143 patients following radiotherapy for locally recurrent rectal cancer. Computerized tomography (CAT) was performed on 45 patients. Of 119 evaluable patients, 54 had a good response to radiotherapy, 29 a moderate response and 36 no apparent response. Median response was 9 and 3 months respectively in the good and moderate groups. Median survival was 15, 9 and 5 months for the three groups. Latent interval between surgery and radiotherapy appeared to be of prognostic importance. When this exceeded 2 yr median survival was 12 months compared with 7 months for patients with a latent interval of less than 2 yr. Tumour volume measured by computed tomography may have prognostic importance. Radiotherapy should be considered for most patients with symptomatic recurrence. Surgery might be combined with radiotherapy for selected groups of patients with good prognosis.

Entities:  

Mesh:

Year:  1983        PMID: 6871637     DOI: 10.1002/bjs.1800700807

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Effect of radiation therapy alone or in combination with surgery and/or chemotherapy on tumor and symptom control of recurrent rectal cancer.

Authors:  H P Knol; P E Hanssens; H J Rutten; T Wiggers
Journal:  Strahlenther Onkol       Date:  1997-01       Impact factor: 3.621

Review 2.  Radiation treatment for rectal cancer.

Authors:  B J Cummings
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

Review 3.  Palliative pelvic radiotherapy of symptomatic incurable rectal cancer - a systematic review.

Authors:  Marte Grønlie Cameron; Christian Kersten; Ingvild Vistad; Sophie Fosså; Marianne Grønlie Guren
Journal:  Acta Oncol       Date:  2013-11-06       Impact factor: 4.089

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.